Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

100%(4 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_1

14%

Ph phase_2

29%

Ph phase_3

57%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

1(14.3%)

Phase 2Efficacy & side effects

2(28.6%)

Phase 3Large-scale testing

4(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(3)

Detailed Status

Completed4

Withdrawn2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (14.3%)

Phase 22 (28.6%)

Phase 34 (57.1%)

Trials by Status

terminated114%

completed457%

withdrawn229%

Recent Activity

0 active trials

Showing 5 of 7

completedphase_2

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

NCT04380961

terminatedphase_3

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

NCT02531633

withdrawnphase_2

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

NCT02794519

completedphase_3

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)

NCT01606761

completedphase_3

A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)

NCT01604343

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT04380961Phase 2

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

Completed

NCT02531633Phase 3

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

Terminated

NCT02794519Phase 2

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

Withdrawn

NCT01606761Phase 3

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)

Completed

NCT01604343Phase 3

A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)

Completed

NCT02899026Phase 3

Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica

Withdrawn

NCT01636557Phase 1

A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7